Budesonide/formoterol anti-inflammatory reliever and maintenance or fluticasone propionate/ salmeterol plus as-needed, short-acting β2 agonist: Real-world effectiveness in patients without optimally controlled asthma (react) study

Shih Lung Cheng, Ming Lin Ho, Yun Fa Lai, Hao Chien Wang, Jeng Yuan Hsu, Shih Feng Liu, Ming Shyang Huang, Cheng Hung Lee, Ching Hsiung Lin, Liang Wen Hang, Yu Chih Liu, Kuang Yao Yang, Jia Horng Wang

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Introduction: In the prospective, observational, 16-week REACT study conducted between October 21, 2008 and May 12, 2011, we compared the real-world effectiveness of anti-inflammatory reliever and maintenance therapy with budesonide/formoterol (Symbicort® Turbuhaler) and maintenance therapy with fixed-dose fluticasone/salmeterol (Seretide®) plus as-needed, short-acting β2 agonists (SABAs) in Taiwanese patients with inadequate asthma control. Methods: Asthma control was assessed using the five-item Asthma Control Questionnaire (ACQ-5) and standardized pulmonary function testing. Assessments were performed at baseline and at weeks 4–5 and 12–16. Overall, we enrolled 842 patients at 11 clinics, 723 of whom were included in analyses (budesonide/formoterol, 563.3±1.3 μg/d, n=551; flutica-sone/salmeterol, 1013.8±1.4 μg/d, n=172). Results: At baseline, 72.5% and 27.5% of all patients had “partly” and “uncontrolled” asthma, respectively. Mean±SD ACQ-5 scores were 1.54±1.06 and 1.46±1.28 in the bude-sonide/formoterol and fluticasone/salmeterol groups, respectively. ACQ-5 scores significantly improved from baseline (ie, decreased) in both groups at weeks 4 and 16. ACQ-5 difference scores were significantly lower in the budesonide/formoterol group (−0.91±1.11) than the fluticasone/salmeterol group (−0.69±1.27) at the end of the study (p=0.027). Peak expiratory flow rate significantly improved from baseline in the budesonide/formoterol but not the fluticasone/salmeterol group at the end of the study. Severe exacerbation rates and medical resource utilization were comparable between the budesonide/formoterol and fluti-casone/salmeterol groups. Conclusion: Collectively, results indicate the real-world effectiveness of budesonide/for-moterol anti-inflammatory reliever and maintenance therapy is better than fixed-dose fluti-casone/salmeterol plus as-needed SABA. Trial Registration: ClinicalTrials.gov registration number: NCT00784953.

Original languageEnglish
Pages (from-to)5441-5450
Number of pages10
JournalDrug Design, Development and Therapy
Volume14
DOIs
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Budesonide/formoterol anti-inflammatory reliever and maintenance or fluticasone propionate/ salmeterol plus as-needed, short-acting β<sub>2</sub> agonist: Real-world effectiveness in patients without optimally controlled asthma (react) study'. Together they form a unique fingerprint.

Cite this